|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 492.80 DKK | -4.16% |
|
-2.99% | -31.13% |
| 12-12 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 12-11 | Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration | RE |
| Capitalization | 34.64B 5.44B 4.64B 4.33B 4.07B 7.5B 493B 8.2B 50.55B 19.61B 232B 20.42B 19.99B 848B | P/E ratio 2025 * |
6x | P/E ratio 2026 * | 29.7x |
|---|---|---|---|---|---|
| Enterprise value | 23.35B 3.67B 3.12B 2.92B 2.75B 5.06B 332B 5.52B 34.07B 13.22B 157B 13.76B 13.47B 571B | EV / Sales 2025 * |
2.62x | EV / Sales 2026 * | 4.62x |
| Free-Float |
99.18% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Zealand Pharma A/S
| 1 day | -4.16% | ||
| 1 week | -2.99% | ||
| Current month | -4.57% | ||
| 1 month | -5.38% | ||
| 3 months | +19.50% | ||
| 6 months | +9.17% | ||
| Current year | -31.13% |
| 1 week | 491.5 |  | 532 |
| 1 month | 485.5 | | 556 |
| Current year | 306.1 | | 808 |
| 1 year | 306.1 | | 809 |
| 3 years | 189.3 | | 972 |
| 5 years | 69.55 | | 972 |
| 10 years | 69.55 | | 972 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 29/03/2022 | |
| Director of Finance/CFO | - | 31/10/2022 | |
David M. Kendall
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/06/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18/04/2018 |
| Director/Board Member | 66 | 03/04/2019 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0% | 51 M€ | +19.39% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.16% | -2.99% | -36.86% | +150.66% | 5.44B | |
| -0.48% | -2.31% | +29.68% | +105.96% | 54.11B | |
| +0.91% | -3.43% | +175.04% | +885.05% | 42.02B | |
| +0.70% | +4.04% | +66.46% | +19.35% | 39.6B | |
| -1.24% | -1.50% | -21.24% | -46.81% | 22.8B | |
| -1.52% | -0.84% | +40.08% | -36.97% | 19.5B | |
| 0.00% | +2.64% | +88.09% | -34.80% | 17.76B | |
| +6.05% | +0.32% | +95.60% | +196.08% | 14.73B | |
| -2.33% | -4.04% | -1.46% | +349.36% | 13.55B | |
| +5.03% | -4.65% | +133.80% | - | 13.14B | |
| Average | +0.30% | -1.41% | +56.92% | +176.43% | 24.26B | |
| Weighted average by Cap. | +0.34% | -1.20% | +67.59% | +216.66% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.92B 1.4B 1.19B 1.12B 1.05B 1.93B 127B 2.11B 13.02B 5.05B 59.82B 5.26B 5.15B 218B | 4.92B 772M 658M 615M 578M 1.06B 69.96B 1.16B 7.17B 2.78B 32.98B 2.9B 2.84B 120B |
| Net income | 5.83B 917M 781M 729M 686M 1.26B 83.01B 1.38B 8.51B 3.3B 39.13B 3.44B 3.37B 143B | 1.16B 183M 156M 146M 137M 252M 16.56B 275M 1.7B 659M 7.81B 686M 672M 28.49B |
| Net Debt | -11.29B -1.77B -1.51B -1.41B -1.33B -2.45B -161B -2.67B -16.48B -6.39B -75.74B -6.66B -6.52B -276B | -11.91B -1.87B -1.59B -1.49B -1.4B -2.58B -169B -2.82B -17.37B -6.74B -79.86B -7.02B -6.87B -291B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 492.80 kr | -4.16% | 478,306 |
| 11/12/25 | 514.20 kr | +0.43% | 366,871 |
| 10/12/25 | 512.00 kr | +1.19% | 296,513 |
| 09/12/25 | 506.00 kr | -3.69% | 329,770 |
| 08/12/25 | 525.40 kr | +3.43% | 333,308 |
Delayed Quote Nasdaq Copenhagen, December 12, 2025 at 04:20 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZEAL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition